Toronto, Ontario – June 15, 2017
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research on phosphorescent photosensitizers was recently presented on June 12th, at the 16th International Photodynamic Association (“IPA”) World Congress held from June 8th to 13th, 2017 in Coimbra, Portugal.
The IPA was founded in 1986 and its membership consists of some of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The IPA promotes the study of diagnosis and clinical treatment using light and Photo Sensitizers (“PSs”), and disseminates this knowledge to IPA members, the medical community and the general public. The IPA World Congress is held every two years and is quickly becoming known as the premier forum to communicate outstanding advances in the clinical and research aspects of PDT and PD.
Angelika Rueck, Ph.D, University of Ulm, presented, “New phosphorescent Photo Sensitizers (“PS”) to follow up PDT response by Fluorescence Lifetime Imaging (“FLIM”) and PS Phosphorescence Lifetime Imaging (“PLIM”).”
Dr. Rueck presented how the Theralase patented PDC, TLD-1433, has demonstrated pre-clinically that:
- It is able to localize to the mitochondria of T-24 human bladder cancer cells and not the nucleus (Effective way to kill cancer cells without nuclear damage)
- Under simultaneous FLIM and PLIM activation the cell’s metabolism and oxygenation during PDT can be measured (By measuring oxygenation levels during PDT, the efficacy of PDT treatment can be optimized)
TLD-1433 PLIM and NADH FLIM can determine oxygenation and cellular metabolism during PDT and hence optimize efficacy of the treatment for various cancer cell types.
Angelika Ruelck, Ph.D. stated that, “FLIM/PLIM allows deep insight into the light induced mechanisms during PDT, allowing Theralase the opportunity to overcome the difficulty of treating under hypoxic (low oxygen) conditions or hypoxic tumour areas, common to cancer cells. The combination of PLIM with PDT treatment planning using TLD-1433, opens new avenues towards increasing patient outcomes during PDT treatment.”
Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is delighted that Dr. Rueck presented the latest research on phosphorescent photosensitizers to such a respected group of international researchers and clinicians at the 16th IPA World Congress. This research will allow Theralase the ability to successfully commercialize this next generation PDT technology for NMIBC and various other cancers.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com .
This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225